peplomycin and Carcinoma--Papillary

A 60-year-old woman was admitted to our hospital with a complaint of rough feeling on the oral mucosa and diagnosed as verrucous carcinoma with histopathological examination. She was treated with CPE chemotherapy, and showed a good response and improvement of clinical symptoms. Toxicities were leukopenia, alopecia and anorexia. However, these were slight side effects. The patient is currently healthy with no recurrence after two years and 3 months. CPE chemotherapy is considered to be effective for a patient with verrucous carcinoma.

Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Papillary; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Middle Aged; Mouth Neoplasms; Peplomycin; Remission Induction

A 70-year-old male complained of a mass on the left side of his tongue. A biopsy specimen was diagnosed as verrucous carcinoma. He was treated with preoperative chemotherapy (UFT, CDDP, PEP) and irradiation, continuous partial glossectomy. The tumor response to chemotherapy was excellent, and no tumor cells were found in the surgical specimen. There was no recurrence of the tumor 1 year and 7 months after therapy. For advanced tumors, preoperative chemotherapy appears to be significantly effective.

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Papillary; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Humans; Male; Peplomycin; Preoperative Care; Radiotherapy Dosage; Tegafur; Tongue Neoplasms; Uracil

A case of metastatic uterine papillary carcinoma with elevated serum carcinoembryonic antigen (CEA) is reported. The patient presented with ascites and pleural effusions and with a high level of CEA (258 ng/ml) 3 months after primary surgical resection and postoperative irradiation had been performed. Her complete response, although temporary, to two kinds of combination chemotherapy was evaluated using serial estimations of the serum CEA.

Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoembryonic Antigen; Carcinoma, Papillary; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Middle Aged; Peplomycin; Uterine Neoplasms; Vinblastine

A phase II study of peplomycin, an analogue of bleomycin, was carried out in 42 patients with advanced or recurrent breast cancer by a cooperative group consisting of 15 institutes throughout Japan, and the following results were obtained. Among the 42 patients, 38 were evaluable, in whom the overall response rate was 7.9% (3/38). For the various histologic types, the response rate was 33.3% (2/6) for papillotubular carcinoma and 9.1% (1/11) for medullary tubular carcinoma. The response rate was 33.3% (2/6) in patients without prior treatment and 3.1% (1/32) in those with prior treatment. Side effects of nausea, anorexia, malaise, alopecia and pyrexia occurred frequently, and a decrease in WBC and an increase in GOT were observed temporally. Pulmonary toxicity was observed in 7 patients.

Topics: Adult; Aged; Anorexia; Bleomycin; Breast Neoplasms; Carcinoma; Carcinoma, Papillary; Drug Evaluation; Female; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Peplomycin

Twelve patients with recurrent breast cancer were treated with Peplomycin monotherapy. Peplomycin was given intermittently with a dose of 10 mg intramuscularly twice a week. As side effects of Peplomycin, fever elevation in 75% (9/12), malaise in 67%, nausea and vomiting in 42%, anorexia in 42%, pulmonary toxicity in 8%, and loss of hair in 8%, were observed. Out of 8 evaluable cases, CR was obtained in 1, PR in 1, NC in 3, and PD in 3 cases, respectively.

Topics: Adult; Aged; Antibiotics, Antineoplastic; Bleomycin; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Papillary; Drug Evaluation; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Peplomycin